FAHD1 and neoplasm: Future efforts to therapeutically exploit this axis may benefit from dual-pronged strategies that simultaneously cripple tumor-intrinsic metabolism (e.g., FAHD1 inhibition) and remodel the immunosuppressive niche, potentially overcoming limitations observed with earlier metabolic agents like DCA.